Avoidance of graft-vs.-host disease (GVHD) after a hematopoietic stem cell transplant could depend on certain members of the microbiome. According to a study led by scientists at the Fred Hutchinson Cancer Center (FHCC), while some species of intestinal bacteria repressed the expression of the major histocompatibility complex II (MHC-II), others induced it and triggered the immune response that produces GVHD. Read More
Bacteria cells are masters of adaptation and evolution, and by better understanding how they adapt and evolve, researchers hope to develop better drugs to fight microbial resistance, which is increasingly becoming a global public health threat. Researchers from the antimicrobial resistance interdisciplinary research group at the Singapore-MIT Alliance for Research and Technology (SMART) sought to understand the mechanisms bacteria use to adapt against stressors, and they discovered a new stress signaling system that sheds light on a new mechanism of antimicrobial resistance. Read More
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. presented the discovery and preclinical evaluation of novel EGFR(T790M/C797S) inhibitors for the treatment of mutant non-small-cell lung cancer (NSCLC). Read More
Researchers from Washington University in St. Louis reported data validating microtubule-binding region (MTBR) of tau containing the residue 243 (MTBR-tau243) as a new cerebrospinal fluid (CSF) biomarker specific for insoluble tau aggregates in Alzheimer’s disease (AD). Read More
Researchers from Harvard Medical School, Yale University and University of Leiden have uncovered two new potential biomarkers of dysregulated glucose metabolism in Alzheimer’s disease (AD). Glucose hypometabolism is consistently observed in AD but the molecular changes behind this are unclear. Findings from recent research have indicated dysregulation of glycolysis markers in AD cerebrospinal fluid (CSF) and tissue. Read More
Shanghai Annova Biotechnology Co. Ltd. has disclosed substituted fused heterocyclic compounds acting as ATR kinase inhibitors reported to be useful for the treatment of cancer. Read More
Hangzhou Polymed Biopharmaceuticals Inc. has synthesized IL-1 receptor-associated kinase 4 (IRAK-4) and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer. Read More
Mabwell (Shanghai) Bioscience Co. has received approval from China's National Medical Products Administration (NMPA) for its clinical trial application for 7MW-3711 for advanced malignant solid tumors. Read More
Shanghai Allist Pharmaceuticals Co. Ltd. has divulged EGFR (HER1; erbB1) (mutant) inhibitors reported to be useful for the treatment of cancer. Read More
Medific Inc. has described substituted thiazolidinedione derivatives acting as sterol regulatory element binding protein (SREBP; SREBF1) inhibitors reported to be useful for the treatment of cancer, particularly brain cancer. Read More
Researchers from the University of Texas and University of Tennessee set out to determine if the long noncoding RNA (lncRNA) MALAT1 (metastasis associated lung adenocarcinoma transcript 1), which is known to regulate a subset of genes involved in synaptic plasticity, cognitive function and memory, plays an important role in Alzheimer’s disease (AD) pathology. Read More
